Nektar Therapeutics Stock on Track for Worst Day Since '04

NKTR stock is now at risk for bearish brokerage attention

Jun 4, 2018 at 9:52 AM
facebook X logo linkedin

Shares of Nektar Therapeutics (NASDAQ:NKTR) have plunged 30.8% to trade at $62.50 -- pacing for their worst day since August 2004 -- after early data from the company's experimental cancer treatment, NKTR-214, with Bristol-Myers Squibb's (BMY) Opdivo failed to meet Wall Street's expectations. Specifically, the response rate fell 50% once 14 additional patients were enrolled in the study, bringing the total number of participants to 27.

Heading into today's trading, NKTR stock had recently bounced from the $75 region after pulling back from its mid-March record high north of $111.36 -- a neighborhood that's home to a 38.2% Fibonacci retracement of the stock's August through March surge, and 140-day moving average. However, the shares are now trading at their lowest point since January, clinging to a positive year-to-date return.

More losses could be ahead should analysts issue downgrades and/or price-target cuts. Of the 10 analysts covering Nektar Therapeutics stock, nine maintain a "strong buy" rating. Plus, the average 12-month price target of $101.56 stands at a 63% premium to NKTR's current price.

Short sellers would certainly welcome more downside. While the security is on the short-sale restricted (SSR) list through tomorrow's trading, short interest jumped 14% in the two most recent reporting periods to 11.69 million shares -- the most since early November.

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI